在局部晚期食道癌患者接受新辅助化疗后间隔转移:一个多中心观察队列研究
Charlène J van der Zijden1, Pieter C van der Sluis2, Bianca Mostert3
1Department of Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. c.vanderzijden@erasmusmc.nl.
Annals of surgical oncology
|July 27, 2024
概括
大约10%的食道癌患者在新辅助化学放射治疗 (nCRT) 后发展间隔转移. 使用18F-FDG-PET/CT的复制是至关重要的,特别是对于寡基质扩散,这可能允许治愈治疗和改善生存率.
科学领域:
- 在瘤学瘤学.
- 医疗成像医学成像
- 手术瘤学手术瘤学
背景情况:
- 食道癌症的治疗往往涉及三模式疗法.
- 10-20%的患者经历了手术后的间隔转移.
- 复位可以识别手术候选人和患有有限转移的患者,以控制疾病.
研究的目的:
- 确定新辅助化疗或放射治疗 (nCRT) 后间隔转移的发生率.
- 评估间隔转移患者的治疗策略和生存结果.
- 评估重新分期在治疗食道癌症患者中的作用.
主要方法:
- 用nCRT治疗的食道癌症患者的回顾性分析.
- 通过18F-FDG-PET/CT或在nCRT后长达14周的手术期间识别转移.
- 转移的分类为寡头转移 (≤3病变) 或非寡头转移.
- 评估整体存活 (OS),转移部位和接受的治疗.
主要成果:
- 973名患者中有10.3%在nCRT后发生间隔转移.
- 在30%的转移患者中发现了寡度转移,主要是在非区域性淋巴结或骨中.
- 寡头转移的中位数生存期为13.8个月,其中40%接受治疗治疗,中位数生存期为22.8个月.
- 患有非橄瘤转移的患者的平均寿命为9个月.
结论:
- 间隔转移发生在nCRT后大约10%的食道癌患者中.
- 18F-FDG-PET/CT重新分期对于手术规划至关重要.
- 一个小组的患者与寡聚转移可能实现有利的存活与适当的治疗.
更多相关视频
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
14.2K
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
8.1K
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
